

B-LCL-HROC112 | 302023

Description	B-LCL-HROC112	B	-	EBV	B	A	T	NK
	B-LCL-HROC112	B	CD19 CD20	CD23 CD80		MHC I	II	
	B-LCL-HROC112	IgG IgM IgA						

Organism

Tissue

Disease

Metastatic site Not applicable (EBV-transformed B-LCL from CRC patient; suspension culture)

Applications T cell and NK cell assays; HLA typing; antigen presentation studies; CTL assay target cells; colorectal cancer immunology; patient-matched HROC biobank studies

Synonyms B-LCL CO112 Bc HROC112

Age 80

Gender

Ethnicity Caucasian

Morphology

Cell type B

Growth properties

Citation B-LCL-HROC112 Cytion 302023

B-LCL-HROC112 | 302023

Biosafety level 2

NCBI_TaxID 9606

CellosaurusAccession Not assigned

GMO Status GMO-S2: This B-LCL contains a stably maintained EBV episome (EBNA-1/-2/-3, LMP-1/-2). EBV is classified as risk group 2; BSL-2 containment required. This classification applies within Germany; regulations may differ elsewhere.

Viruses EBV

Culture Medium RPMI 1640 w 2.0 mM w 2.0 g/L NaHCO3 Cytion 820700a

Supplements 10% FBS

Subculturing ⁵ / 1×10

Freeze medium FBS +10% DMSO CM-1 Cytion 800100 CM-1 Cytion 800100

B-LCL-HROC112 | 302023

Thawing and Culturing Cells				
1.				
2.		-150°C		3
3.		37°C	40-60	
4.			70%	
5.		8	15	
6.	300 x g	3		
7.	10		T25	T25
8.				

Incubation Atmosphere 37°C, 5% CO₂

Flask Coating

Freezing Procedure -78 °C

Shipping Conditions -78 °C

Storage Conditions -150 -196 -80 °C

/ /HLA

Sterility PCR